RecruitingObese Adults
A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities
Eligible age
18–60 yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.
Sponsor: Viking Therapeutics, Inc.
You may qualify if…
- ✓ Must be capable of giving a signed informed consent form (ICF).
- ✓ Must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the study Investigator.
- ✓ BMI ≥ 30 kg/m2.
- ✓ Willing to comply with contraceptive requirements.
You may not qualify if…
- ✕ Participants with any level of disease or organ system dysfunction as identified during physical examination, medical history, or laboratory testing, as assessed by the Investigator.
- ✕ Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion or drug absorption.
- ✕ Any condition that might compromise safety or other endpoints in the study as judged by the Sponsor (or designee) or Investigator.
- ✕ History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant.
- ✕ Current or past diagnosis of diabetes mellitus (including type 1 and type 2, except gestational diabetes).
- ✕ Have a personal or family history of medullary thyroid carcinoma (MTC) or have multiple endocrine neoplasia syndrome type 2 (MEN-2).
- ✕ Alanine aminotransferase (ALT) level or aspartate transaminase (AST) level \> 3.0 times the ULN for the reference range.
- ✕ Impaired renal function with estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2 as measured at Screening.
Where it's recruiting
California
Lake Forest
Florida
Miami
Source: ClinicalTrials.gov · NCT07838740 · last updated 2026-09-24